Gil Roth10.30.13
Algorithme Pharma has signed a strategic alliance with the University of Montreal Hospital Research Centre (CRCHUM), allowing access to both an extensive pool of patients and CRCHUM's 520,000-sq.-ft. research complex for conducting complex early stage clinical trials. This partnership will also provide access to CRCHUM’s diverse research groups with extensive clinical research experience in therapeutic areas including Oncology, Neuroscience, Cardio-Metabolic Diseases and Respiratory Disorders.
CRCHUM is a new research complex located in downtown Montreal, Quebec. It includes a cyclotron, a state-of-the-art medical-imaging platform, 75 laboratories, 36 clinical examination rooms, 15 beds for early stage clinical trials, a specialized research pharmacy, as well as the Integrated Center for Education and Training (CIEF).
“The need for patient populations for early stage clinical trials continues to increase as drug development companies look for Proof of Concept (POC) of their lead drug. This partnership will help advance the goal of providing a full spectrum of Phase I/IIa clinical research services in a diverse range of patient populations, to meet these growing needs” stated Dr. Marc Lefebvre, vice-president Scientific & Regulatory Affairs, Algorithme Pharma Inc.
“We look forward to working with Algorithme Pharma closely and adding to our expertise in early stage clinical research. Working with a team focused on providing solutions to complex clinical issues in key therapeutic areas will allow us to stand out on the international drug development landscape” stated Dr. Jacques Turgeon, director of CRCHUM.
CRCHUM is a new research complex located in downtown Montreal, Quebec. It includes a cyclotron, a state-of-the-art medical-imaging platform, 75 laboratories, 36 clinical examination rooms, 15 beds for early stage clinical trials, a specialized research pharmacy, as well as the Integrated Center for Education and Training (CIEF).
“The need for patient populations for early stage clinical trials continues to increase as drug development companies look for Proof of Concept (POC) of their lead drug. This partnership will help advance the goal of providing a full spectrum of Phase I/IIa clinical research services in a diverse range of patient populations, to meet these growing needs” stated Dr. Marc Lefebvre, vice-president Scientific & Regulatory Affairs, Algorithme Pharma Inc.
“We look forward to working with Algorithme Pharma closely and adding to our expertise in early stage clinical research. Working with a team focused on providing solutions to complex clinical issues in key therapeutic areas will allow us to stand out on the international drug development landscape” stated Dr. Jacques Turgeon, director of CRCHUM.